---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-107154"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:52:15.678838+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Olema reports FY2025 net loss of $162.5M; cash $505.4M; OPERA-01 data fall 2026

## Summary
- Net loss Q4 $46.1M, full year $162.5M; R&D expenses $43.2M and $157.7M respectively.
- Cash and marketable securities $505.4M; raised $218.5M in public offering.
- Phase 3 OPERA-01 top-line data expected fall 2026; Phase 1b/2 with Pfizer atirmociclib initiated.
- OP-3136 initial clinical data expected Q2 2026; commercial launch prep for potential late 2027 approval.

## SEC filing metadata
- accession: 0001193125-26-107154
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/0001193125-26-107154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/olma-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-107154
- JSON: https://secwatch.observer/filing/0001193125-26-107154.json
- Plain text: https://secwatch.observer/filing/0001193125-26-107154.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the quarter and year ended December 31, 2025 was $46.1 million and $162.5 million, respectively.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Net income: Net loss for the quarter and year ended December 31, 2025 was $46.1 million and $162.5 million, respectively
  - Result: reported results
  source text: On March 16, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/0001193125-26-107154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.